There is no turning back to pre-COVID clinical trial methods. It is expected that over 50% of clinical trials will be decentralized by 2024, and biopharma companies that adapt to this change slowly can expect to lose market share quickly. Decentralized and hybrid clinical trials eliminate geographic barriers and improve patient participation rates and diversity – as long as your teams are properly trained and have the right partners and technology.
DGE invites you to return to the industry’s first, most detailed, and most trusted conference on this topic – our 7th Decentralized & Hybrid Clinical Trials Summit. Join us in Philadelphia, May 10th-11th, to shape best practice on:
- Refining patient recruitment strategy
- Quickly upscaling digital technologies
- Prioritizing patient diversity
- Adapting biospecimen collection and management methods
- Benefiting from retail pharmacy partners.
- Clinical Trials / Research / Operations / Processes
- Decentralized Trials
- Trial Design
- Clinical Innovation / Development
- Clinical Quality / Sourcing
- Remote Monitoring
- Patient Recruitment / Experience / Solutions
- Clinical Projects / Data / Supply Chain
- Clinical Safety / Regulatory Affairs
- Outsourcing
- Digital Health
- Site Solutions / Management
- Medical Affairs
“I wanted to understand more about where other pharma companies are in the process of building up these platforms. This exceeded my expectations!” – Director, Clinical Operations, NOVO NORDISK
“Every presentation was incredibly informative and led to further thinking and discussion. I truly enjoyed how the event felt like a meeting of people all fully interested in addressing and solving a glaring problem in the clinical research world.” – Senior Director, Clinical Technology, LEO PHARMA
